Investment Rating - The investment rating for the company is "Outperform the Market" [6][4]. Core Insights - In 2024, the company achieved a revenue of 1.346 billion (up 23.1%) and a net profit of 274 million (up 50.4%), driven by increased demand for orthopedic products and effective cost management [10][4]. - The company is focusing on expanding its overseas market presence and has seen significant growth in its international revenue, which reached 274 million (up 20.8%), accounting for 20.4% of total revenue [15][4]. - The company is leveraging its 3D printing technology and digital orthopedic solutions to create a comprehensive ecosystem, enhancing its competitive edge in the market [24][23]. Revenue and Profitability - The revenue from hip joint implants was 729 million (up 23.5%), and knee joint implants generated 405 million (up 30.1%) in 2024, indicating a strong recovery in surgical volumes [15][2]. - The gross profit margin for 2024 was 60.0%, with a net profit margin of 20.3%, reflecting effective cost control measures [20][3]. - The company has maintained a focus on research and development, with a R&D expense ratio of 10.3%, while also managing other expenses effectively [20][3]. Financial Forecasts - The company has slightly adjusted its profit forecasts for 2025-2026, now expecting net profits of 334 million, 404 million, and 484 million for 2025, 2026, and 2027 respectively, with growth rates of 21.9%, 20.8%, and 20.0% [4][5]. - The current price-to-earnings (PE) ratios are projected to be 19.2, 15.9, and 13.2 for 2025, 2026, and 2027 respectively, indicating a favorable valuation compared to historical performance [4][5]. Market Position and Strategy - The company is recognized as a leader in the orthopedic market, being the first in China to commercialize 3D printing technology for joint implants, which strengthens its market position [24][4]. - The strategic focus on digital orthopedic solutions and international expansion is expected to drive future growth, with the company successfully entering new markets [24][15].

报名：首届全球心血管大会 | 奖项申报 # 财报数据 报名：首届全球骨科大会 | 奖项评选 报名：首届全球眼科大会 | 议程更新 2024年公司 收入达13.46亿元人民币，同比增长23.1% 。公司权益股东应占年度溢利为2.74亿元，同比增长 50.4%。基本每股盈利0.25元，摊薄每股盈利0.24元。拟派发末期股息每股7.2港仙。 毛利达到约8.08亿元，增 长19.8% 。 合作伙伴征集：2025全球手术机器人大会 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至12月31日止年度 | | | | | 2024年 | 2023年 | 變動百分比 | | | 人民幣千元 | 人民幣千元 | 96 | | 收入 | 1,346,377 | 1,093,862 | 23.1% | | 毛利 | 808.193 | 674.486 | 19.8% | | 年内溢利 | 273,926 | 182,104 | 50.4% | | 本公司權益股東應佔年度溢利 | 273,926 | 182,104 | 50.4% | | 每股盈利 | | | | | 基本 | 人民幣0 ...

报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月7日， 捷迈邦美Zimmer Biomet （纽约证券交易所代码：ZBH）宣布，其 Persona Revision SoluTion Femur（股骨）膝关节植入物组件 已获得美国食品药品监督管理局（FDA）的510(k)许可。 该组件是 Persona膝关节翻修系统（Persona Revision Knee System） 的一部分，为某些金属敏感的患者提 供了一种替代方案。它采用了一种专有的表面硬化处理技术，旨在提高耐磨性能。该产品为外科医生提供了一 系列解剖组件，包括胫骨和股骨锥，以及多种茎选择，以解决区域固定问题。 合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 # 产品介绍 皮肤金属过敏影响着10%-15%的普通人群，而带有金属植入物的患者中这一比例可能高达25%。当患者接 触到某些常用于金属膝关节植入物的金属时，可能会出现炎症反应、疼痛和植入物松动等问题。 而 Persona Revision SoluTion Femur膝关节植入物 是一款专为膝关节翻修手术 ...